Zydus Gets USFDA Nod For Dapagliflozin Tabs

Mumbai, Feb 23: Pharma major Zydus has received final approval from the USFDA to market Dapagliflozin Tablets of 5 mg and 10 mg strength. Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Dapagliflozin also lowers the risk of heart failure in adults with type 2 diabetes and heart disease.

It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), hospitalization for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.